Expiration date: 01/2025

Clinico-pharmacological group

Oral hypoglycemic agents

Pharmacological action

Metformin inhibits hepatic gluconeogenesis, reduces glucose absorption from the intestines, enhances peripheral glucose utilization and increases the sensitivity of tissues to insulin. When this has no effect on insulin secretion from the beta cells of the pancreas, does not cause hypoglycemic reactions. Lowers triglycerides and lipoproteinov low density in the blood. Stabilizes or reduces body weight. Provides fibrinoliticescoe effects by suppressing the inhibitor of plasminogen activator of tissue type.

Disease

Diabetes mellitus type 2 (insulin)

Testimony

— diabetes mellitus type 2 without propensity to ketoatsidozu (especially in patients suffering from obesity) when poor diet;

— in combination with insulin - diabetes mellitus type 2, especially in severe degree of obesity accompanied by secondary insulin resistance.

Terms and conditions storage

Store in a dry, protected from light place at a temperature of from 15° to 25°C. Keep out of reach of children. Gnosti period of 3 years.